NATH BIOGENES (INDIA)
Back to Balance Sheet
|
NATH BIOGENES (INDIA) Last 5 Year Contingent Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2013 | Mar2012 | |
---|---|---|---|---|---|
Contingent Liabilities | ₹92 Cr | ₹72 Cr | ₹61 Cr | ₹0.34 Cr | ₹0.26 Cr |
What is the latest Contingent Liabilities ratio of NATH BIOGENES (INDIA) ?
Year | Contingent Liabilities |
---|---|
Mar2024 | ₹92 Cr |
Mar2023 | ₹72 Cr |
Mar2022 | ₹61 Cr |
Mar2013 | ₹0.34 Cr |
Mar2012 | ₹0.26 Cr |
How is Contingent Liabilities of NATH BIOGENES (INDIA) Trending?
Years | Contingent Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹92 Cr | 28.60 | |
Mar2023 | ₹72 Cr | 18.58 | |
Mar2022 | ₹61 Cr | 17,668.04 | |
Mar2013 | ₹0.34 Cr | 33.73 | |
Mar2012 | ₹0.26 Cr | - |
Compare Contingent Liabilities of peers of NATH BIOGENES (INDIA)
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
NATH BIOGENES (INDIA) | ₹302.1 Cr | -5.6% | 1.9% | -16.4% | Stock Analytics | |
BOMBAY BURMAH TRADING CORPORATION | ₹13,295.0 Cr | -0.8% | 6.7% | 26.7% | Stock Analytics | |
KAVERI SEED COMPANY | ₹7,349.6 Cr | -8.1% | 12.8% | 87.4% | Stock Analytics | |
VENKYS (INDIA) | ₹2,392.0 Cr | -1.6% | 1% | -2.2% | Stock Analytics | |
BOMBAY SUPER HYBRID SEEDS | ₹1,429.6 Cr | -12.8% | 8.2% | -36.7% | Stock Analytics | |
INDO US BIOTECH | ₹340.9 Cr | -1.9% | 8.4% | -29.5% | Stock Analytics |
NATH BIOGENES (INDIA) Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
NATH BIOGENES (INDIA) | -5.6% |
1.9% |
-16.4% |
SENSEX | 0.8% |
3.8% |
8.4% |
You may also like the below Video Courses